文献速递甲状腺疾病

评估不确定甲状腺结节分子诊断试验临床验证研究的偏倚与局限性:系统综述与荟萃分析

Assessing Bias and Limitations of Clinical Validation Studies of Molecular Diagnostic Tests for Indeterminate Thyroid Nodules: Systematic Review and Meta-Analysis.
PubMed 文献 · Thyroid · 2022-09-26

该系统综述与荟萃分析检索截至2021年7月的PubMed、EMBASE和Web of Science,纳入49项报告真阴性、真阳性、假阴性、假阳性计数的分子诊断试验临床验证研究,评估Afirma与ThyroSeq等检测的准确性并量化八种常见偏倚与局限性。荟萃分析显示各检测诊断准确性较高,但研究存在多种局限性,需加以处理并在可行时用有效统计方法校正。

要点

  • Afirma GEC(38项研究)灵敏度0.92、特异度0.26,阴性似然比0.32。
  • ThyroSeq v1和v2(10项研究)灵敏度0.86、特异度0.74,阳性似然比3.52。
  • 仅14%研究对切除结节行盲法组织病理学复核,8%手术决策对分子检测结果设盲。

核心结论

  • 荟萃分析显示分子检测对甲状腺结节恶性肿瘤风险评估具有较高诊断准确性,但这些研究受多种局限性影响,需加以处理并在可行时用有效统计方法学校正。

研究设计与样本

  • 系统检索PubMed、EMBASE和Web of Science截至2021年7月,纳入报告真阴性、真阳性、假阴性、假阳性计数的英文原创临床验证研究,共49项。
  • 对八种常见偏倚与局限性进行评估,提取诊断与组织病理学信息,并采用双变量线性混合效应模型进行临床有效性荟萃分析。

主要发现

  • Afirma GEC(38项研究)灵敏度0.92(95%CI 0.90-0.94)、特异度0.26(0.20-0.32)、阴性似然比0.32(0.23-0.44)、阳性似然比1.24(1.15-1.35)、AUC 0.83(0.74-0.89)。
  • Afirma GSC(10项研究)灵敏度0.94(0.89-0.96)、特异度0.38(0.27-0.50)、阴性似然比0.18(0.10-0.30)、阳性似然比1.52(1.28-1.87)、AUC 0.91(0.62-0.92)。
  • ThyroSeq v1和v2(10项研究)灵敏度0.86(0.82-0.90)、特异度0.74(0.59-0.85)、阴性似然比0.19(0.13-0.26)、阳性似然比3.52(2.08-5.92)、AUC 0.86(0.81-0.90)。
  • ThyroSeq v3(6项研究)灵敏度0.92(0.86-0.95)、特异度0.41(0.18-0.69)、阴性似然比0.24(0.09-0.62)、阳性似然比1.67(1.09-2.98)、AUC 0.90(0.63-0.92)。
  • 14%的研究对切除甲状腺结节行盲法组织病理学复核,8%的研究手术决策对分子检测结果设盲。

局限性

  • 研究存在多种局限性,其潜在临床影响必须加以处理并在可行时用有效统计方法学校正。
  • 仅14%的研究对切除甲状腺结节行盲法组织病理学复核。
  • 仅8%的研究手术决策对分子检测结果设盲。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Molecular tests for thyroid nodules with indeterminate fine needle aspiration results are increasingly used in clinical practice; however, true diagnostic summaries of these tests are unknown. A systematic review and meta-analysis were completed to (1) evaluate the accuracy of commercially available molecular tests for malignancy in indeterminate thyroid nodules and (2) quantify biases and limitations in studies that validate those tests. Summary: PubMed, EMBASE, and Web of Science were systematically searched through July 2021. English language articles that reported original clinical validation attempts of molecular tests for indeterminate thyroid nodules were included if they reported counts of true-negative, true-positive, false-negative, and false-positive results. We performed screening and full-text review, followed by assessment of eight common biases and limitations, extraction of diagnostic and histopathological information, and meta-analysis of clinical validity using a bivariate linear mixed-effects model. Forty-nine studies were included. Meta-analysis of Afirma Gene expression classifiers (GEC; n = 38 studies) revealed a sensitivity of 0.92 (confidence interval: 0.90-0.94), specificity of 0.26 (0.20-0.32), negative likelihood ratio (LR-) of 0.32 (0.23-0.44), positive LR+ of 1.24 (1.15-1.35), and area under the curve (AUC) of 0.83 (0.74-0.89). Afirma Genomic Sequencing Classifier (GSC; n = 10) had a sensitivity of 0.94 (0.89-0.96), specificity of 0.38 (0.27-0.50), LR- of 0.18 (0.10-0.30), LR+ of 1.52 (1.28-1.87), and AUC of 0.91 (0.62-0.92). ThyroSeq v1 and v2 (n = 10) had a sensitivity of 0.86 (0.82-0.90), specificity of 0.74 (0.59-0.85), LR- of 0.19 (0.13-0.26), LR+ of 3.52 (2.08-5.92), and AUC of 0.86 (0.81-0.90). ThyroSeq v3 (n = 6) had a sensitivity of 0.92 (0.86-0.95), specificity of 0.41 (0.18-0.69), LR- of 0.24 (0.09-0.62), LR+ of 1.67 (1.09-2.98), and AUC of 0.90 (0.63-0.92). Fourteen percent of studies conducted a blinded histopathologic review of excised thyroid nodules, and 8% made the decision to go to surgery blind to molecular test results. Conclusions: Meta-analyses reveal a high diagnostic accuracy of molecular tests for thyroid nodule assessment of malignancy risk; however, these studies are subject to several limitations. Limitations and their potential clinical impacts must be addressed and, when feasible, adjusted for using valid statistical methodologies.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. DiGennaro C, Vahdatzad V, Jalali MS, et al. Assessing Bias and Limitations of Clinical Validation Studies of Molecular Diagnostic Tests for Indeterminate Thyroid Nodules: Systematic Review and Meta-Analysis. Thyroid. 2022. PMID: 35999710. doi:10.1089/thy.2022.0269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。